120 related articles for article (PubMed ID: 2212728)
1. Delayed antigen presentation by epidermal Langerhans cells to cloned T h1 and T h2 cells.
Tiegs SL; Evavold BD; Yokoyama A; Stec S; Quintans J; Rowley D
J Invest Dermatol; 1990 Oct; 95(4):446-9. PubMed ID: 2212728
[TBL] [Abstract][Full Text] [Related]
2. In vitro evidence that Langerhans cells can adopt two functionally distinct forms capable of antigen presentation to T lymphocytes.
Streilein JW; Grammer SF
J Immunol; 1989 Dec; 143(12):3925-33. PubMed ID: 2592763
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antigen-presenting capacity of cultured Langerhans' cells is associated with markedly increased expression of Ia antigen.
Shimada S; Caughman SW; Sharrow SO; Stephany D; Katz SI
J Immunol; 1987 Oct; 139(8):2551-5. PubMed ID: 3498764
[TBL] [Abstract][Full Text] [Related]
4. Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells.
Romani N; Koide S; Crowley M; Witmer-Pack M; Livingstone AM; Fathman CG; Inaba K; Steinman RM
J Exp Med; 1989 Mar; 169(3):1169-78. PubMed ID: 2522497
[TBL] [Abstract][Full Text] [Related]
5. Functional dichotomy between Langerhans cells that present antigen to naive and to memory/effector T lymphocytes.
Streilein JW; Grammer SF; Yoshikawa T; Demidem A; Vermeer M
Immunol Rev; 1990 Oct; 117():159-83. PubMed ID: 2258190
[TBL] [Abstract][Full Text] [Related]
6. Antigen presentation by Langerhans cells in vivo: donor-derived Ia+ Langerhans cells are required for induction of delayed-type hypersensitivity but not for cytotoxic T lymphocyte responses to alloantigens.
Peeler JS; Niederkorn JY
J Immunol; 1986 Jun; 136(12):4362-71. PubMed ID: 3519767
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance.
Enk AH; Angeloni VL; Udey MC; Katz SI
J Immunol; 1993 Sep; 151(5):2390-8. PubMed ID: 8103065
[TBL] [Abstract][Full Text] [Related]
8. Antigen processing by epidermal Langerhans cells correlates with the level of biosynthesis of major histocompatibility complex class II molecules and expression of invariant chain.
Puré E; Inaba K; Crowley MT; Tardelli L; Witmer-Pack MD; Ruberti G; Fathman G; Steinman RM
J Exp Med; 1990 Nov; 172(5):1459-69. PubMed ID: 2121888
[TBL] [Abstract][Full Text] [Related]
9. Antigen processing and presentation by epidermal Langerhans cells. Induction of immunity or unresponsiveness.
Cruz PD; Bergstresser PR
Dermatol Clin; 1990 Oct; 8(4):633-47. PubMed ID: 1979019
[TBL] [Abstract][Full Text] [Related]
10. Antigen presenting capacity of Langerhans cells from rat oral epithelium.
Hasséus B; Dahlgren U; Bergenholtz G; Jontell M
J Oral Pathol Med; 1995 Feb; 24(2):56-60. PubMed ID: 7745542
[TBL] [Abstract][Full Text] [Related]
11. Ultraviolet B radiation converts Langerhans cells from immunogenic to tolerogenic antigen-presenting cells. Induction of specific clonal anergy in CD4+ T helper 1 cells.
Simon JC; Tigelaar RE; Bergstresser PR; Edelbaum D; Cruz PD
J Immunol; 1991 Jan; 146(2):485-91. PubMed ID: 1670944
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 1 alpha but not transforming growth factor beta inhibits tumor antigen presentation by epidermal antigen-presenting cells.
Grabbe S; Bruvers S; Granstein RD
J Invest Dermatol; 1994 Jan; 102(1):67-73. PubMed ID: 8288913
[TBL] [Abstract][Full Text] [Related]
13. A small number of anti-CD3 molecules on dendritic cells stimulate DNA synthesis in mouse T lymphocytes.
Romani N; Inaba K; Puré E; Crowley M; Witmer-Pack M; Steinman RM
J Exp Med; 1989 Mar; 169(3):1153-68. PubMed ID: 2522496
[TBL] [Abstract][Full Text] [Related]
14. Immunologic aspects of acute cutaneous graft-versus-host disease: decreased density and antigen-presenting function of Ia+ Langerhans cells and absent antigen-presenting capacity of Ia+ keratinocytes.
Breathnach SM; Shimada S; Kovac Z; Katz SI
J Invest Dermatol; 1986 Mar; 86(3):226-34. PubMed ID: 2427602
[TBL] [Abstract][Full Text] [Related]
15. Immunologic properties of purified epidermal Langerhans cells. Distinct requirements for stimulation of unprimed and sensitized T lymphocytes.
Inaba K; Schuler G; Witmer MD; Valinksy J; Atassi B; Steinman RM
J Exp Med; 1986 Aug; 164(2):605-13. PubMed ID: 3487618
[TBL] [Abstract][Full Text] [Related]
16. The effect of cyclosporine on epidermal cells. I. Cyclosporine inhibits accessory cell functions of epidermal Langerhans cells in vitro.
Furue M; Katz SI
J Immunol; 1988 Jun; 140(12):4139-43. PubMed ID: 3259608
[TBL] [Abstract][Full Text] [Related]
17. Langerhans cells transport Leishmania major from the infected skin to the draining lymph node for presentation to antigen-specific T cells.
Moll H; Fuchs H; Blank C; Röllinghoff M
Eur J Immunol; 1993 Jul; 23(7):1595-601. PubMed ID: 8325337
[TBL] [Abstract][Full Text] [Related]
18. In vivo treatment with anti-I-A antibodies: differential effects on Ia antigens and antigen-presenting cell function of spleen cells and epidermal Langerhans cells.
Aberer W; Kruisbeek AM; Shimada S; Katz SI
J Immunol; 1986 Feb; 136(3):830-6. PubMed ID: 3455705
[TBL] [Abstract][Full Text] [Related]
19. The role of human epidermal Langerhans cells in skin immunity.
Braathen LR
Derm Beruf Umwelt; 1987; 35(2):58-61. PubMed ID: 2439270
[TBL] [Abstract][Full Text] [Related]
20. Epidermal cells as accessory cells in the generation of allo-reactive and hapten-specific cytotoxic T lymphocyte (CTL) responses.
Steiner G; Wolff K; Pehamberger H; Stingl G
J Immunol; 1985 Feb; 134(2):736-41. PubMed ID: 2578162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
